{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:20Z","timestamp":1792785860115,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Science & Engineering Research Board \u2013 Department of Science & Technology"},{"name":"SERB-DST","award":["SERB\/ECR\/2017\/000317"],"award-info":[{"award-number":["SERB\/ECR\/2017\/000317"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/cvr\/cvy226","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T13:31:35Z","timestamp":1535549495000},"page":"373-384","source":"Crossref","is-referenced-by-count":58,"title":["Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy"],"prefix":"10.1093","volume":"115","author":[{"given":"Vajir","family":"Malek","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B1","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B2","volume-title":"Global Status Report on Noncommunicable Diseases","author":"WHO","year":"2014"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-8703(99)70082-7","article-title":"Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure","volume":"138","author":"Northridge","year":"1999","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-6175.2002.01506.x","article-title":"The rise and fall of omapatrilat","volume":"4","author":"Pickering","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"AJHYPE"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B9","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/j.hlc.2015.06.236","article-title":"LCZ696, an angiotensin receptor neprilysin inhibitor, attenuates renal fibrosis after myocardial infarction and reduces angiotensin-II-mediated renal cellular collagen synthesis","volume":"24","author":"Wang","year":"2015","journal-title":"Heart Lung Circ"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B10","first-page":"45.","article-title":"Nine new analyses show Novartis\u2019 LCZ696 could change course of heart failure for patients","volume":"22","author":"Carroll","year":"2014","journal-title":"Nine"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B11","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.jacc.2015.08.877","article-title":"LCZ696 (sacubitril\/valsartan): can we predict who will benefit?","volume":"66","author":"Dec","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B12","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B13","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.cardfail.2015.06.158","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fraction","volume":"21","author":"Solomon","year":"2015","journal-title":"J Cardiac Fail"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B15","doi-asserted-by":"crossref","first-page":"e1000412.","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B16","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1042\/BCJ20160595","article-title":"Histone H2AK119 and H2BK120 mono-ubiquitination modulate SET7\/9 and SUV39H1 in type 1 diabetes-induced renal fibrosis","volume":"473","author":"Goru","year":"2016","journal-title":"Biochem J"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejphar.2015.09.035","article-title":"Insulin sensitizing and cardioprotective effects of Esculetin and Telmisartan combination by attenuating Ang II mediated vascular reactivity and cardiac fibrosis","volume":"765","author":"Kadakol","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B18","doi-asserted-by":"crossref","first-page":"e0180490.","DOI":"10.1371\/journal.pone.0180490","article-title":"Dysregulation of microRNAs and renin-angiotensin system in high salt diet-induced cardiac dysfunction in uninephrectomized rats","volume":"12","author":"Amara","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12012-012-9187-6","article-title":"Terminalia arjuna improves cardiovascular autonomic neuropathy in streptozotocin-induced diabetic rats","volume":"13","author":"Khaliq","year":"2013","journal-title":"Cardiovasc Toxicol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jff.2015.05.017","article-title":"Esculetin reverses histone H2A\/H2B ubiquitination, H3 dimethylation, acetylation and phosphorylation in preventing type 2 diabetic cardiomyopathy","volume":"17","author":"Kadakol","year":"2015","journal-title":"J Funct Foods"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B21","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/bph.13946","article-title":"Diminazene aceturate prevents nephropathy by increasing glomerular Ace2 and At2 receptor expression in a rat model of type1 diabetes","volume":"174","author":"Goru","year":"2017","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B22","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/db15-0871","article-title":"Baroreflex sensitivity impairment during hypoglycemia: implications for cardiovascular control","volume":"65","author":"Rao","year":"2016","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B24","first-page":"C16","article-title":"GW28-e0555 Telmisartan in the diabetic murine model of acute myocardial infarction evaluated by dual contrast manganese-enhanced and delayed enhancement MRI","volume":"70","author":"Qin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B25","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2174\/1381612822666160928150040","article-title":"The role of PPARs in pathological cardiac hypertrophy and heart failure","volume":"23","author":"Liao","year":"2017","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2337\/dc06-1551","article-title":"Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes","volume":"30","author":"Schmieder","year":"2007","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/01.HYP.0000215181.60228.f7","article-title":"Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis","volume":"47","author":"Sugimoto","year":"2006","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1139\/cjpp-2014-0416","article-title":"Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS\u2013ERK and PI3K\u2013Akt\u2013eNOS pathways in spontaneously hypertensive rats","volume":"93","author":"Wang","year":"2015","journal-title":"Can J Physiol Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ajh.2011.34","article-title":"Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome","volume":"24","author":"Khan","year":"2011","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor\u2013neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin\u2010induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition versus AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin Sci"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B32","doi-asserted-by":"crossref","first-page":"e002560.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B33","first-page":"5473","article-title":"LCZ696 (Sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD","volume":"9","author":"Jing","year":"2017","journal-title":"Am J Transl Res"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B34","doi-asserted-by":"crossref","first-page":"e006617.","DOI":"10.1161\/JAHA.117.006617","article-title":"Angiotensin II receptor\u2013neprilysin inhibitor sacubitril\/valsartan improves endothelial dysfunction in spontaneously hypertensive rats","volume":"6","author":"Seki","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis and vasculopathy in a rat model of chronic kidney disease","author":"Suematsu","year":"2018","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1262-3636(07)70059-9","article-title":"Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?","volume":"29","author":"Cosson","year":"2003","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","article-title":"LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy","volume":"108","author":"Xia","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B38","doi-asserted-by":"crossref","first-page":"e00336.","DOI":"10.1002\/prp2.336","article-title":"Prevention against renal damage in rats with subtotal nephrectomy by sacubitril\/valsartan (LCZ696), a dual\u2010acting angiotensin receptor\u2010neprilysin inhibitor","volume":"5","author":"Ushijima","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/cvr\/cvx011","article-title":"An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy","volume":"113","author":"Frati","year":"2017","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/cvr\/cvx018","article-title":"Metabolic remodelling in diabetic cardiomyopathy","volume":"113","author":"Chong","year":"2017","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe","year":"2018","journal-title":"Cell Death Dis"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B42","doi-asserted-by":"crossref","first-page":"a022210.","DOI":"10.1101\/cshperspect.a022210","article-title":"TGF-\u03b2 signaling in control of cardiovascular function","volume":"10","author":"Goumans","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cge.12121","article-title":"Epigenetic changes in diabetes","volume":"84","author":"Keating","year":"2013","journal-title":"Clin Genet"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ki.2015.148","article-title":"Recent developments in epigenetics of acute and chronic kidney diseases","volume":"88","author":"Reddy","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jdiacomp.2016.08.001","article-title":"Imbalance between HDAC and HAT activities drives aberrant STAT1\/MyD88 expression in macrophages from type 1 diabetic mice","volume":"31","author":"Filgueiras","year":"2017","journal-title":"J Diabetes Complications"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B47","doi-asserted-by":"crossref","first-page":"F14","DOI":"10.1152\/ajprenal.00200.2010","article-title":"The role of epigenetics in the pathology of diabetic complications","volume":"299","author":"Villeneuve","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/ki.2013.387","article-title":"Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db\/db mice","volume":"85","author":"Reddy","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00125-017-4490-1","article-title":"Epigenetics in diabetic nephropathy, immunity and metabolism","volume":"61","author":"Keating","year":"2018","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B50","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1096\/fj.201601116R","article-title":"Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney","volume":"31","author":"Deb","year":"2017","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","article-title":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications","volume":"93","author":"Tikoo","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B52","first-page":"256","article-title":"Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications","volume":"35","author":"Kadakol","year":"2017","journal-title":"Indian J Pharmacol"},{"key":"key\n\t\t\t\t2019012203583434000_cvy226-B53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbrc.2017.04.134","article-title":"Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis","volume":"487","author":"Pandey","year":"2017","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/2\/373\/27566837\/cvy226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T16:16:27Z","timestamp":1661876187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/2\/373\/5090455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,9,4]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvy226","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2018,9,4]]}}}